Longeveron Inc. (LGVN)
| Previous close | 3.7500 |
| Open | 3.8400 |
| Bid | 3.8800 x 800 |
| Ask | 3.9200 x 2200 |
| Day's range | 3.8000 - 3.9700 |
| 52-week range | 2.8400 - 45.0000 |
| Volume | |
| Avg. volume | 329,707 |
| Market cap | 80.551M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8820 |
| Earnings date | 14 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.02 |
- GlobeNewswire
Longeveron Names Jerome Bailey Vice President of Business Operations
Executive brings more than 30 years of global biopharmaceutical operations and program management experienceMIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations. He joins the company from Checkmate Pharmaceuticals (acquired by Regeneron), where he served as senior director of pr
- GlobeNewswire
Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference
MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place in New York City from September 12-14, 2022. Longeve
- GlobeNewswire
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants
New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting approximately 1,000 babies per yearMIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Lomecel-B™ for t
